Zydus Lifesciences has launched Anyra, India’s first indigenously developed biosimilar of Aflibercept 2 mg, aimed at treating visual impairment caused by retinal disorders, including complications arising from diabetes.
The Gujarat-based pharmaceutical major stated that Anyra is indicated for the treatment of visual impairment resulting from conditions such as diabetic macular edema and other retinal diseases.
Expanding Access to Retinal Care
With over 100 million people living with diabetes in India, the burden of diabetes-related vision complications remains significant. The launch of a domestically developed biosimilar is expected to improve accessibility and affordability of advanced biologic therapies in ophthalmology.
Managing Director Sharvil P Patel said the launch marks a significant step toward strengthening affordable retinal care in India.
“We are committed to making advanced biologics accessible to patients who need them most. Anyra represents a transformative step in expanding access to high-quality, indigenously developed Aflibercept 2 mg therapies,” Patel stated.
Strategic Collaboration
Zydus also announced that it has entered into an agreement with Regeneron Pharmaceuticals Inc. and Bayer in relation to Anyra. Further details of the agreement were not disclosed.
Market Significance
Biosimilars are increasingly becoming a key growth area in the Indian pharmaceutical sector, particularly in high-cost biologics used in oncology and ophthalmology. With Anyra, Zydus strengthens its biologics portfolio and reinforces its positioning in specialty therapies.
The launch is expected to support the company’s long-term strategy of expanding its footprint in complex generics and biosimilars.
